ESSEX BIO-TECH (01061) Enters Exclusive Distribution Agreement with OSTEOPORE

Stock News
01/15

ESSEX BIO-TECH (01061) announced that on January 15, 2026, its wholly-owned subsidiary, Majeton Pte Ltd (Majeton), entered into an exclusive distribution agreement with Osteopore International Pte Ltd (Osteopore). Osteopore is a global leader in the field of 3D-printed, bionic, and bio-absorbable implants. Under the distribution agreement, Osteopore has appointed Majeton as its exclusive distributor for innovative dental, orthodontic, and maxillofacial products in Mainland China, Hong Kong, and Macau. The anticipated contract value of the distribution agreement exceeds RMB 12 million, which includes upfront and milestone payments, with the potential for further additional revenue generated through product procurement and supply. This collaboration with Osteopore marks a significant milestone for the Group in the oral care market, expanding its portfolio of dental, orthodontic, and maxillofacial solutions, and will collectively support the Group's pursuit of sustainable growth in the Chinese market.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10